Vivos Therapeutics (VVOS) Free Cash Flow (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Free Cash Flow data on file, last reported at -$6.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 53.44% year-over-year to -$6.0 million in Q1 2026; TTM through Mar 2026 was -$22.5 million, a 55.23% decrease from a year earlier, with the FY2025 full-year figure at -$20.4 million, down 54.12% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$6.0 million, up from -$8.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for VVOS reached as high as -$2.4 million in Q3 2023 and fell as low as -$8.1 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$4.3 million across 5 years, with a median of -$3.9 million in 2025.
• Across the five-year window, Free Cash Flow surged 60.18% in 2023 and plunged 161.34% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$3.2 million in 2022, then slipped by 7.53% to -$3.5 million in 2023, then climbed by 9.87% to -$3.1 million in 2024, then plunged by 161.34% to -$8.1 million in 2025, then advanced by 26.05% to -$6.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$6.0 million in Q1 2026, -$8.1 million in Q4 2025, and -$4.1 million in Q3 2025.